Vascular Endothelial Growth Factor (VEGF) and Heparin-Binding Potential

Vascular endothelial growth factor (VEGF-A165) displays multiple effects, such as promoting endothelial growth and vascular permeability and hypotension, through binding to its receptor, KDR (kinase domain-containing receptor) [1–3]. Heparan sulfate/heparin-like molecules greatly contribute to their interaction. Indeed, the mitogenic potency of VEGF-A165 lacking the C-terminal heparin-binding region is less than 1% compared with intact VEGF-A165. We previously found novel heparin-binding VEGFs, designated VEGF-F that specifically recognizes KDR in snake venoms. VEGF-Fs almost completely lack the C-terminal heparin-binding region compared with VEGF-A165, despite their heparin-binding potential. In this study, we attempted to identify the heparin-binding region of VEGF-F using synthetic peptides. We have demonstrated that the heparin-binding site of VEGF-F is located in its C-terminal region, particularly localized on the N-terminal portion of this region. Furthermore, a synthetic peptide of this region blocks the biological activity of VEGF-A165 in vitro and in vivo.

Key Words
Vascular endothelial growth factor • Snake venom • Heparin-binding protein

Abbreviations
VEGF-A165: Vascular endothelial growth factor (165-amino acid residues); KDR: Kinase domain-containing receptor; VR-1: Vammin-like VR-1

Acknowledgments
This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

References
not retained from a heparin affinity column and displayed markedly reduced (greater than 100-fold) potency of growth factor activity when compared with intact VEGF-A165 [4]. VEGF-Fs are ~25-kDa homodimeric heparin-binding proteins. The primary structure of VEGF-Fs possesses ~50% identity with that of VEGF-A165, and they have a markedly short C-terminal portion (16–17 amino acid residues) when compared with VEGF-A165. This region does not include cysteine bridges, and does not show any significant homology with other proteins or domains, including the C-terminal heparin-binding region of other VEGF subtypes.

We herein report the C-terminal region of VEGF-F fully mediates its heparin-binding activity and inhibits the biological activity of VEGF-A165 in vitro and in vivo. These results suggest that the C-terminal peptide of VEGF-F inhibits the biological activity of VEGF-A165 via binding to heparin-like molecules.

Identification of Heparin-Binding Region of Snake Venom VEGF and VEGF-Blocking Activity

We first synthesized the C-terminal region of vammin (corresponding to residues 94–110; 17 residues), designated peptide 1. Peptide 1 was purified by two steps column chromatography; heparin affinity chromatography followed by reversed-phase HPLC. Peptide 1 and intact vammin were tested for heparin-binding ability using heparin affinity chromatography. Heparin-binding potential of vammin and peptide 1 were virtually equivalent as determined by the NaCl concentrations required for elution (0.33 and 0.36 M, respectively), indicating that the heparin-binding activity is completely mediated by the C-terminal region.

We speculated that if the C-terminal heparin-binding region of vammin recognizes similar heparin structures, it competes with VEGF-A165 on the endothelial surface and inhibits the biological activities of VEGF-A165. The effect of peptide 1 on endothelial cell proliferation activity of vammin or VEGF-A165 was thus investigated. Peptide 1 completely inhibited both vammin- and VEGF-A165-stimulated endothelial proliferation with similar IC50 values (320 and 280 μM, respectively). We also examined the effect of peptide 1 on rat arterial blood pressure in vivo. Administration of peptide 1 (3 μg/g, 5 min before following vammin administration) via femoral vein completely blocked the vammin (0.1 μg/g)-induced hypotensive effect. In contrast, a higher dose of peptide 1 (30 μg/g) was required to completely inhibit VEGF-A165-induced hypotension. These results indicate that peptide 1 is able to block the biological activity of VEGF-A165 even in vivo.

Further Localization of Heparin-Binding Site in Peptide 1 Sequence

To further investigate localization of heparin-binding site of peptide 1, we synthesized two additional peptides that correspond to N- or C-terminal part of peptide 1, designated peptide 2 (corresponding to residues 94–101; 9 residues) and peptide 3 (corresponding to residues 102–110; 11 residues), respectively. The heparin-binding potential of synthetic peptides was assessed by heparin affinity chromatography. Peptide 2 was eluted at 0.34 M NaCl, showing almost identical activity to vammin and peptide 1 for heparin binding. In contrast, peptide 3 was not retained after washing the column with NaCl-free buffer, indicating substantially lower affinity to the heparin column. These data indicate that the basic residues

Identification of Heparin-Binding Region of Snake Venom VEGF

Pathophysiol Haemost Thromb 2005;34:194–196

195
clustered in the N-terminal portion of peptide 1 primarily mediate the heparin-binding function.

We next evaluated the effect of synthetic peptides on VEGF-A165 activity using cultured human umbilical vein endothelial cells. Relatively weak inhibition was observed in peptide 2-treated cells when compared with peptide 1, while peptide 3 had an even smaller effect, thus showing good agreement with the heparin-binding affinity data. These results strongly suggest that the basic amino acid residues in peptide 2 primarily mediate the heparin-binding activity of VEGF-Fs, but are not sufficient for binding and that the C-terminal portion (peptide 3 region) is also involved in the interaction. In addition, we also estimated the effect of synthetic peptides on VEGF-A165-induced hypotension. When pre-treatment of peptide 2, VEGF-A165-induced hypotension completely blocked as well as pre-treatment of peptide 1. These in vivo data show good agreement with the in vitro results obtained using cultured endothelial cells.

**Conclusion**

In conclusion, we have demonstrated that the heparin-binding site of VEGF-F is located in its C-terminal short region, particularly localized in the N-terminal portion of peptide 1 region. Furthermore, a synthetic peptide of this region blocks the biological activity of VEGF-A165 in vitro and in vivo. Because this heparin-binding region has a relatively small structure, it may be a valuable tool for designing new anticancer drugs that target VEGF-heparin interaction.

**References**


3. Li B, Ogasawara AK, Yang R, Wei W, He GW, Zioncheck TF, Bunting S, de Vos AM, Jin H: KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension 2002;39:1095–1100.
